Stratatech News

October 01, 2009

Stratatech Corp. receives $1.7 million grant for skin cancer treatment

Stratatech Corp., Madison, has received a $1.7 million grant from the National Cancer Institute to develop a new product aimed at treating skin cancer. The cell-based, gene therapy product would be used after surgical removal of the tumor. The living skin substitute is designed to stimulate the patient's immune system to eliminate any cancerous cells that remain after the tumor is removed. The National Cancer Institute estimates more than 1 million cases of skin cancer will be diagnosed in the U.S. this year, including more than 62,000 new cases of melanoma.